128 related articles for article (PubMed ID: 37409790)
1. Spasmodic Dysphonia Patients' Perception of Pain with Botulinum Toxin Injections.
Heffernan A; Hu A
Laryngoscope; 2024 Jan; 134(1):240-246. PubMed ID: 37409790
[TBL] [Abstract][Full Text] [Related]
2. Factors Associated with Failure of Botulinum Toxin Injection in Adductor Spasmodic Dysphonia.
Zhao K; Guillaud M; Hu A
Ann Otol Rhinol Laryngol; 2020 Oct; 129(10):996-1002. PubMed ID: 32468829
[TBL] [Abstract][Full Text] [Related]
3. Alternating Unilateral Versus Bilateral Injections of Botulinum Toxin for the Treatment of Adductor Spasmodic Dysphonia.
Lee SJ; Kang MS; Choi HS; Lim JY
Otolaryngol Head Neck Surg; 2021 Apr; 164(4):815-820. PubMed ID: 32957836
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Botulinum Toxin Injections and Type 2 Thyroplasty for Adductor Spasmodic Dysphonia.
Sanuki T; Takemoto N
Laryngoscope; 2023 Dec; 133(12):3443-3448. PubMed ID: 37278482
[TBL] [Abstract][Full Text] [Related]
5. Unilateral versus bilateral botulinum toxin injections in adductor spasmodic dysphonia in a large cohort.
Dharia I; Bielamowicz S
Laryngoscope; 2020 Nov; 130(11):2659-2662. PubMed ID: 31837152
[TBL] [Abstract][Full Text] [Related]
6. Adductor spasmodic dysphonia: Botulinum toxin a injections or laser thyroarytenoid myoneurectomy? A comparison from the patient perspective.
Schuering JHC; Heijnen BJ; Sjögren EV; Langeveld APM
Laryngoscope; 2020 Mar; 130(3):741-746. PubMed ID: 31169922
[TBL] [Abstract][Full Text] [Related]
7. Factors influencing long-term treatment response to botulinum toxin injection for spasmodic dysphonia.
Kang MS; Lee SJ; Choi HS; Lim JY
Clin Otolaryngol; 2021 Mar; 46(2):436-444. PubMed ID: 33260261
[TBL] [Abstract][Full Text] [Related]
8. Retrospective review of dosing trends in botulinum toxin injections for the treatment of adductor spasmodic dysphonia in a long-term cohort.
French G; Bosch JD; Randall DR
J Otolaryngol Head Neck Surg; 2020 Jan; 49(1):4. PubMed ID: 31937363
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the efficacy and adverse effects of unilateral or bilateral botulinum toxin injections for adductor spasmodic dysphonia: a systematic review and meta-analysis.
Liu Y; Chen F; Liang F; Wang C; Chen D; Zhou J; Zhang L; Xiao X; He R; Tang L; Tian L; Zhou L
Eur Arch Otorhinolaryngol; 2024 Mar; 281(3):1357-1369. PubMed ID: 38095707
[TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin treatment of false vocal folds in adductor spasmodic dysphonia: Functional outcomes.
Simpson CB; Lee CT; Hatcher JL; Michalek J
Laryngoscope; 2016 Jan; 126(1):118-21. PubMed ID: 26467807
[TBL] [Abstract][Full Text] [Related]
11. Liquid-type Botulinum Toxin Type A in Adductor Spasmodic Dysphonia: A Prospective Pilot Study.
Cha W; Jang JY; Wang SG; Kang JH; Jo MG
J Voice; 2017 May; 31(3):378.e19-378.e24. PubMed ID: 27520509
[TBL] [Abstract][Full Text] [Related]
12. Association of Laryngeal Botulinum Neurotoxin Injection With Work Productivity for Patients With Spasmodic Dysphonia.
Meyer TK; Spiekerman C; Kaye R; Blitzer A; Kamizi RS; Jiang L; Weaver EM
JAMA Otolaryngol Head Neck Surg; 2021 Sep; 147(9):804-810. PubMed ID: 34351425
[TBL] [Abstract][Full Text] [Related]
13. Analgesia in Transcutaneous Laryngeal Botulinum Toxin Injections: A Randomized Crossover Trial.
Heyes R; Adler CH; Yee C; Lott DG; Karle WE
Laryngoscope; 2024 May; 134(5):2277-2281. PubMed ID: 38157199
[TBL] [Abstract][Full Text] [Related]
14. Interarytenoid muscle botox injection for treatment of adductor spasmodic dysphonia with vocal tremor.
Kendall KA; Leonard RJ
J Voice; 2011 Jan; 25(1):114-9. PubMed ID: 20137891
[TBL] [Abstract][Full Text] [Related]
15. Botulinum Toxin Dosing Trends in Spasmodic Dysphonia Over a 20-year Period.
Namin AW; Christopher KM; Eisenbeis JF
J Voice; 2017 Jan; 31(1):107-110. PubMed ID: 27005439
[TBL] [Abstract][Full Text] [Related]
16. Quality of Life After Botulinum Toxin Injection in Patients With Adductor Spasmodic Dysphonia; a Systematic Review and Meta-analysis.
Faham M; Ahmadi A; Silverman E; Harouni GG; Dabirmoghaddam P
J Voice; 2021 Mar; 35(2):271-283. PubMed ID: 31477348
[TBL] [Abstract][Full Text] [Related]
17. Factors influencing botulinum toxin dose instability in spasmodic dysphonia patients.
Rosow DE; Pechman A; Saint-Victor S; Lo K; Lundy DS; Casiano RR
J Voice; 2015 May; 29(3):352-5. PubMed ID: 25242042
[TBL] [Abstract][Full Text] [Related]
18. Common practices in botulinum toxin injection for spasmodic dysphonia treatment: A national survey.
Shoffel-Havakuk H; Rosow DE; Lava CX; Hapner ER; Johns MM
Laryngoscope; 2019 Jul; 129(7):1650-1656. PubMed ID: 30582627
[TBL] [Abstract][Full Text] [Related]
19. Treatment efficacy of electromyography versus fiberscopy-guided botulinum toxin injection in adductor spasmodic dysphonia patients: a prospective comparative study.
Kim JW; Park JH; Park KN; Lee SW
ScientificWorldJournal; 2014; 2014():327928. PubMed ID: 25383369
[TBL] [Abstract][Full Text] [Related]
20. Botulinum toxin-B injection into the lacrimal gland and posterior cricoarytenoid muscle for the treatment of epiphora and abductor spasmodic dysphonia secondary to Parkinson's disease.
Sachdev A; Costello D; Madge S
Orbit; 2019 Jun; 38(3):248-251. PubMed ID: 29939826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
